Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 376

1.

Human papillomavirus vaccines: current status and future prospects.

Garland SM, Smith JS.

Drugs. 2010 Jun 18;70(9):1079-98. doi: 10.2165/10898580-000000000-00000. Review.

PMID:
20518577
3.

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP).

MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.

4.

Cervical cancer vaccine development.

Frazer IH.

Sex Health. 2010 Sep;7(3):230-4. doi: 10.1071/SH09132. Review.

PMID:
20719210
5.

Age-appropriate use of human papillomavirus vaccines in the U.S.

Castle PE, Fetterman B, Akhtar I, Husain M, Gold MA, Guido R, Glass AG, Kinney W.

Gynecol Oncol. 2009 Aug;114(2):365-9. doi: 10.1016/j.ygyno.2009.04.035. Epub 2009 May 22. Review.

8.

The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.

Sigurdsson K, Sigvaldason H, Gudmundsdottir T, Sigurdsson R, Briem H.

Acta Obstet Gynecol Scand. 2009;88(1):27-35. doi: 10.1080/00016340802566770.

PMID:
19031282
9.

Human papillomavirus vaccines: an update for gynecologists.

Ault KA.

Clin Obstet Gynecol. 2008 Sep;51(3):527-32. doi: 10.1097/GRF.0b013e31818092df. Review.

PMID:
18677145
10.

Human papillomavirus vaccines versus cervical cancer screening.

Stanley M.

Clin Oncol (R Coll Radiol). 2008 Aug;20(6):388-94. doi: 10.1016/j.clon.2008.04.006. Epub 2008 Jun 5. Review.

PMID:
18538554
11.

Prophylactic HPV vaccination: past, present, and future.

Castle PE, Maza M.

Epidemiol Infect. 2016 Feb;144(3):449-68. doi: 10.1017/S0950268815002198. Epub 2015 Oct 2. Review.

PMID:
26429676
12.

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075171
13.

Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).

McKeage K, Romanowski B.

BioDrugs. 2011 Aug 1;25(4):265-9. doi: 10.2165/11206830-000000000-00000.

PMID:
21815703
14.

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.

Castellsagué X, Schneider A, Kaufmann AM, Bosch FX.

Gynecol Oncol. 2009 Dec;115(3 Suppl):S15-23. doi: 10.1016/j.ygyno.2009.09.021. Epub 2009 Oct 12.

PMID:
19819540
15.

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; HPV PATRICIA Study Group.

Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8. Erratum in: Lancet Oncol. 2012 Jan;13(1):e1.

PMID:
22075170
16.

Cancers attributable to human papillomavirus infection.

Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.

Sex Health. 2010 Sep;7(3):244-52. doi: 10.1071/SH10020.

PMID:
20719211
17.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: Lancet. 2010 Sep 25;376(9746):1054.

PMID:
19586656
18.

Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age.

Harper DM.

Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S11-7. doi: 10.1016/j.ygyno.2008.06.029. Epub 2008 Jul 22.

PMID:
18649932
19.

[Human papillomavirus prophylactic vaccines: stakes and perspectives].

Hantz S, Alain S, Denis F.

Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):647-55. Epub 2006 Jun 27. Review. French.

PMID:
16807045
20.

Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.

Poljak M.

Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Epub 2012 Aug 6. Review.

Supplemental Content

Support Center